PL3113774T3 - Kompozycje grapiprantu i sposoby ich zastosowania - Google Patents

Kompozycje grapiprantu i sposoby ich zastosowania

Info

Publication number
PL3113774T3
PL3113774T3 PL15758877T PL15758877T PL3113774T3 PL 3113774 T3 PL3113774 T3 PL 3113774T3 PL 15758877 T PL15758877 T PL 15758877T PL 15758877 T PL15758877 T PL 15758877T PL 3113774 T3 PL3113774 T3 PL 3113774T3
Authority
PL
Poland
Prior art keywords
grapiprant
compositions
methods
same
Prior art date
Application number
PL15758877T
Other languages
English (en)
Inventor
Lesley Rausch-Derra
Tamara NEWBOLD
Gopinath DEVARAJ
Akemi Shiraishi
Original Assignee
Elanco Animal Health Incorporated
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=54016294&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL3113774(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Elanco Animal Health Incorporated filed Critical Elanco Animal Health Incorporated
Publication of PL3113774T3 publication Critical patent/PL3113774T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/64—Sulfonylureas, e.g. glibenclamide, tolbutamide, chlorpropamide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Pain & Pain Management (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Rheumatology (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
PL15758877T 2014-03-06 2015-03-05 Kompozycje grapiprantu i sposoby ich zastosowania PL3113774T3 (pl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201461948957P 2014-03-06 2014-03-06
US201462089713P 2014-12-09 2014-12-09
EP15758877.3A EP3113774B1 (en) 2014-03-06 2015-03-05 Compositions of grapiprant and methods for using the same
PCT/US2015/019037 WO2015134792A1 (en) 2014-03-06 2015-03-05 Compositions of grapiprant and methods for using the same

Publications (1)

Publication Number Publication Date
PL3113774T3 true PL3113774T3 (pl) 2022-06-13

Family

ID=54016294

Family Applications (1)

Application Number Title Priority Date Filing Date
PL15758877T PL3113774T3 (pl) 2014-03-06 2015-03-05 Kompozycje grapiprantu i sposoby ich zastosowania

Country Status (15)

Country Link
US (3) US11369621B2 (pl)
EP (1) EP3113774B1 (pl)
JP (1) JP6419857B2 (pl)
KR (1) KR102270323B1 (pl)
CN (2) CN105939713A (pl)
AU (1) AU2015227059B2 (pl)
CA (1) CA2941008C (pl)
DK (1) DK3113774T3 (pl)
ES (1) ES2907285T3 (pl)
MX (3) MX376175B (pl)
PL (1) PL3113774T3 (pl)
PT (1) PT3113774T (pl)
RU (1) RU2679631C2 (pl)
TW (2) TWI708606B (pl)
WO (1) WO2015134792A1 (pl)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12109218B2 (en) * 2014-12-09 2024-10-08 Aratana Therapeutics, Inc. Compositions of grapiprant and methods for using the same
DK3113774T3 (da) * 2014-03-06 2022-03-07 Elanco Animal Health Incorporated Sammensætninger af grapiprant og fremgangsmåder til anvendelse deraf
EP3820480A4 (en) 2018-07-11 2022-03-09 Arrys Therapeutics, Inc. POLYMORPHIC COMPOUNDS AND USES THEREOF
EP3856177A4 (en) * 2018-09-27 2022-06-29 Arrys Therapeutics, Inc. Grapiprant unit dosage forms
CN115697317A (zh) * 2020-04-08 2023-02-03 株式会社AskAt Ep4受体拮抗剂用于治疗肝癌、黑色素瘤、淋巴瘤和白血病的应用

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DZ2479A1 (fr) 1997-05-05 2003-02-01 Pfizer Composés inhibiteurs sélectifs de cox-2 anti-inflammatoires et compositions pharmaceutiques les contenant.
JP2003506404A (ja) * 1999-08-10 2003-02-18 グラクソ グループ リミテッド 治療、とりわけ神経障害性疼痛および結腸癌の治療におけるｅｐ４受容体リガンドの使用
HN2001000224A (es) * 2000-10-19 2002-06-13 Pfizer Compuestos de imidazol condensado con arilo o heteroarilo como agentes anti - inflamatorios y analgesicos.
WO2003008637A2 (en) 2001-07-17 2003-01-30 Xanthus Life Sciences, Inc. Use of genotyping in the individualization of therapy
EP1450813B1 (en) * 2001-10-31 2007-08-29 Medical Research Council Antagonists of prostaglandin receptors ep2 and/or ep4 for the treatment of menorrhagia
MXPA04009243A (es) 2002-04-12 2005-06-08 Pfizer Uso de ligandos para el receptor ep4 en el tratamiento de enfermedades vinculadas a il-6.
WO2005102389A2 (en) 2004-04-20 2005-11-03 Pfizer Products Inc. Combinations comprising alpha-2-delta ligands and ep4 receptor antagonists
US7960407B2 (en) * 2005-03-11 2011-06-14 Requalia Pharma Inc. Crystal forms of an imidazole derivative
JP5244091B2 (ja) 2006-04-24 2013-07-24 メルク カナダ インコーポレイテッド Ｅｐ４受容体アンタゴニストとしてのインドールアミド誘導体
US20080242713A1 (en) * 2007-03-28 2008-10-02 Bayer Schering Pharma Aktiengesellschaft Novel 5-cyano-prostacyclin derivatives as agents for the treatment of autoimmune diseases
MX341482B (es) 2010-02-22 2016-08-22 Raqualia Pharma Inc Antagonistas del receptor ep4 y su uso en el tratamiento de enfermedades mediadas por la il-23.
WO2011124525A1 (de) * 2010-04-08 2011-10-13 Boehringer Ingelheim International Gmbh Arnzeimittelkombinationen enthaltend pde4-inhibitoren und ep4-rezeptor-antagonisten
EP2627318B1 (en) 2010-10-12 2017-08-16 Merz Pharma GmbH & Co. KGaA Formulation suitable for stabilizing proteins, which is free of mammalian excipients
MX2013010306A (es) * 2011-03-08 2013-12-09 Zalicus Pharmaceuticals Ltd Formulaciones de dispersion solida y metodos de uso de las mismas.
US9187463B2 (en) 2011-05-18 2015-11-17 Raqualia Pharma Inc. Polymorph form of 4-{[4-({[4-(2,2,2-trifluoroethoxy)-1,2-benzisoxazol-3-yl]oxy}methyl)piperidin-1-yl]methyl}-tetrahydro-2H-pyran-4-carboxylic acid
ITBO20110461A1 (it) * 2011-07-29 2013-01-30 Alfa Wassermann Spa Composizioni farmaceutiche comprendenti rifaximina, processi per la loro preparazione e loro uso nel trattamento di infezioni vaginali.
CN107496421A (zh) 2013-03-19 2017-12-22 株式会社ＡｓｋＡｔ Ep4受体拮抗剂在软骨疾病的治疗中的用途
CN107400132A (zh) 2014-03-06 2017-11-28 阿莱塔纳治疗学股份有限公司 Grapiprant的结晶形式
US12109218B2 (en) * 2014-12-09 2024-10-08 Aratana Therapeutics, Inc. Compositions of grapiprant and methods for using the same
DK3113774T3 (da) * 2014-03-06 2022-03-07 Elanco Animal Health Incorporated Sammensætninger af grapiprant og fremgangsmåder til anvendelse deraf

Also Published As

Publication number Publication date
KR20160129887A (ko) 2016-11-09
WO2015134792A1 (en) 2015-09-11
US11369621B2 (en) 2022-06-28
RU2016137926A (ru) 2018-04-09
US20150250773A1 (en) 2015-09-10
AU2015227059A1 (en) 2016-09-22
RU2019102384A3 (pl) 2022-03-31
EP3113774A4 (en) 2017-10-25
EP3113774A1 (en) 2017-01-11
CA2941008A1 (en) 2015-09-11
MX376175B (es) 2025-03-07
TWI708606B (zh) 2020-11-01
ES2907285T3 (es) 2022-04-22
MX2020001428A (es) 2020-03-20
JP6419857B2 (ja) 2018-11-07
RU2019102384A (ru) 2019-03-04
TW201603812A (zh) 2016-02-01
MX2022014763A (es) 2023-01-11
CN105939713A (zh) 2016-09-14
RU2679631C2 (ru) 2019-02-12
KR102270323B1 (ko) 2021-06-29
TW201815393A (zh) 2018-05-01
TWI664969B (zh) 2019-07-11
NZ761827A (en) 2021-03-26
US20160317559A1 (en) 2016-11-03
AU2015227059B2 (en) 2018-11-15
CN112370450A (zh) 2021-02-19
CA2941008C (en) 2022-07-26
DK3113774T3 (da) 2022-03-07
US12478633B2 (en) 2025-11-25
JP2017507190A (ja) 2017-03-16
MX2016011025A (es) 2016-11-29
NZ724007A (en) 2021-02-26
PT3113774T (pt) 2022-02-28
EP3113774B1 (en) 2022-01-26
US20250025481A1 (en) 2025-01-23

Similar Documents

Publication Publication Date Title
IL259576A (en) Preparations and methods for immuno-oncology
ZA201701244B (en) Carrier-antibody compositions and methods of making and using the same
GB2535253B (en) Compositions and methods
GB2546350B (en) Compositions and methods
GB2535423B (en) Cementing compositions and methods
HUE056172T2 (hu) Szelenoorganikus vegyületeket tartalmazó készítmények és eljárások alkalmazásukra
GB201718876D0 (en) Antithrombin-heparin compositions and methods
ZA202104969B (en) Compositions comprising 15-hepe and methods of using the same
IL246879B (en) Preparations of Epilimod and methods of using them
GB201417828D0 (en) New methods and compositions
EP3166892A4 (en) Scale-inhibition compositions and methods of making and using the same
PL3113774T3 (pl) Kompozycje grapiprantu i sposoby ich zastosowania
GB201715820D0 (en) Compositions and methods
GB201705626D0 (en) Compositions and methods
ZA201606594B (en) Defoamer compositions and methods of using the same
EP3207029A4 (en) Tryptamide compositions and methods of use
GB201512996D0 (en) Compositions and methods
ZA201807665B (en) Methods and compositions
EP3221366A4 (en) Polyaminomethylbenzyloxalamides and compositions and methods related thereto
GB201514413D0 (en) Compositions and methods
GB201402915D0 (en) Compositions and methods
ZA201807782B (en) Methods and compositions
IL256261B (en) Hide1 compositions and methods
GB201403212D0 (en) Compositions and methods
GB201522554D0 (en) Methods and compositions